Kodiak Phase 3 GLOW NPDR study meets primary endpoint; plans to resume tarcocimab

Kodiak Sciences Inc.

GLOW met primary endpoint: 41.1% vs 1.4% achieved >=2-step DRSS improvement (p<0.0001).
Sight-threatening complications risk reduced 89%: 2.3% vs 21.0% (p<0.0001).
DME development risk reduced 95%: 0.7% tarcocimab vs 13.7% sham.
Kodiak pauses then resumes tarcocimab; plans one additional pivotal study for single BLA for wAMD, RVO, NPDR.
Serious ocular adverse events and intraocular inflammation rates similar between groups.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.